These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 33503878)

  • 1. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.
    Michałowska J; Miller-Kasprzak E; Bogdański P
    Nutrients; 2021 Jan; 13(2):. PubMed ID: 33503878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
    Thondam SK; Cuthbertson DJ; Wilding JPH
    Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
    Opinto G; Natalicchio A; Marchetti P
    Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretins in obesity and diabetes.
    Chia CW; Egan JM
    Ann N Y Acad Sci; 2020 Feb; 1461(1):104-126. PubMed ID: 31392745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiology of incretins in health and disease.
    Deacon CF; Ahrén B
    Rev Diabet Stud; 2011; 8(3):293-306. PubMed ID: 22262068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
    João AL; Reis F; Fernandes R
    Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin hormones, obesity and gut microbiota.
    Angelini G; Russo S; Mingrone G
    Peptides; 2024 Aug; 178():171216. PubMed ID: 38636809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretins.
    Wu T; Rayner CK; Horowitz M
    Handb Exp Pharmacol; 2016; 233():137-71. PubMed ID: 25903418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on incretin hormones.
    Phillips LK; Prins JB
    Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease.
    Zarrinpar A; Loomba R
    Aliment Pharmacol Ther; 2012 Nov; 36(10):909-21. PubMed ID: 23057494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.
    Targher G; Mantovani A; Byrne CD
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):179-191. PubMed ID: 36620987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.